ScripsAmerica Inc. (SCRCQ)

[coolerheadsprevail]

With rapimeds...again. It's out of scrc's hands right now. Bob said he's on the phone daily with Hong Kong. Just waiting on the permission to ship and out the door they go.

Yes, it will happen when it will happen... ...but that has never been the problem nor the source of angst for shareholders.

The problem has been that due to BS Schneiderman's repeated intentional lies about RapiMed, the market clearly has been unwillingly to price in ANY speculative value at all into the sp the way it does all the time for many other penny stocks in OTC-land.

There is a reason for the old adage: Fool me once, shame on you; fool me twice, shame on me.

BS Schneiderman has intentionally issued false statements in his PR's on two separate ocassions now w/regards to declaring that regulatory approvals have been successfully obtained in Hong Kong and that SCRC (thru its distributor, GlobalPharmaHub) is now free to begin selling/distributing RapiMed within the Hong Kong territory.

Not only that, but he has also knowingly issued false PR's re: sales trips to China and the imminent signing of large scale contracts with pharmacy and retail networks involving "thousands" of outlets in China.

And when the Street sees that the timing of these intentionally false PR's (not to mention hyperbolic claims that RapiMed would rival Main Ave in annual revenues at a time when Main Ave was running at a $64M/year run rate) coincide with when shares of either the 0.00 stock or the 0.05 PIPE stock held by the homophobic criminal JOSEPH ZAMPETTI and his proud associates are unlocking -- well, it doesn't take a rocket scientist to put 2 and 2 together at this point.

Point being, shareholders are being harmed because REGARDLESS of whether RapiMed launches or not, the Street is punishing shareholders here and now for BS Schneiderman's lack of credibility.

And I'll leave you with this:

Regardless of whether SCRC can physically ship RapiMed to Hong Kong, there is NOTHING preventing GPH from moving forward all this time and signing up customers and securing actual sales orders for RapiMed. This is not an uncommon practice in situations like this where a sales contract would be signed that would simply be contingent upon obtaining regulatory clearance to bring the physical inventory into the country. There is ZERO reason why -- if there were actually any interest in RapiMed in Hong Kong -- SCRC should not have been PR'ing each month the existence of new sales order commitments over the past year by now.